Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane

dc.contributor.authorAlam, Walid
dc.contributor.authorBouferraa, Youssef
dc.contributor.authorHaibe, Yolla
dc.contributor.authorShamseddine, Ali I.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Hematology Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:01:11Z
dc.date.available2025-01-24T12:01:11Z
dc.date.issued2021
dc.description.abstractAdrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Treatment options for ACC are limited, with resection the main intervention. Most cases present in late metastatic cases, and data regarding effective therapies is limited. We report a case of ACC in a 40-year-old woman with history of ACC postadrenalectomy, who presented with recurrent metastatic ACC in the left perinephric space. She was started on pembrolizumab which was added to her mitotane maintenance therapy. Complete radiological response was achieved after 4 cycles of pembrolizumab. As far as we know, this is the first case to achieve complete radiological response with mitotane and pembrolizumab in recurrent metastatic ACC, with negative prognostic markers and no prior radiotherapy. As our findings are in the setting of one clinical case, we suggest the need to perform a trial to assess the benefit of combining mitotane and pembrolizumab in treating metastatic ACC. © The Author(s) 2021.
dc.identifier.doihttps://doi.org/10.1177/11795549211007682
dc.identifier.eid2-s2.0-85104237810
dc.identifier.urihttp://hdl.handle.net/10938/31441
dc.language.isoen
dc.publisherSAGE Publications Ltd
dc.relation.ispartofClinical Medicine Insights: Oncology
dc.sourceScopus
dc.subjectAcc
dc.subjectAdrenocortical carcinoma
dc.subjectComplete radiological response
dc.subjectImmunoscore
dc.subjectMitotane
dc.subjectPembrolizumab
dc.subjectRegulatory t-cells
dc.subjectTumor-associated macrophages
dc.subjectFluorodeoxyglucose
dc.subjectAdrenal cortex carcinoma
dc.subjectAdult
dc.subjectArticle
dc.subjectCancer localization
dc.subjectCancer radiotherapy
dc.subjectCancer surgery
dc.subjectCase report
dc.subjectCd3+ t lymphocyte
dc.subjectCd8+ t lymphocyte
dc.subjectClinical article
dc.subjectClinical feature
dc.subjectDisease severity
dc.subjectDrug efficacy
dc.subjectDrug safety
dc.subjectFemale
dc.subjectGene amplification
dc.subjectHigh throughput sequencing
dc.subjectHuman
dc.subjectHuman tissue
dc.subjectMaintenance therapy
dc.subjectMultiple cycle treatment
dc.subjectNuclear magnetic resonance imaging
dc.subjectPatient history of adrenalectomy
dc.subjectPositron emission tomography-computed tomography
dc.subjectRecurrent metastatic adrenal cortex carcinoma
dc.subjectRegulatory t lymphocyte
dc.subjectTreatment response
dc.subjectTumor growth
dc.subjectTumor volume
dc.subjectTumor-associated macrophage
dc.titleComplete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021-2804.pdf
Size:
490.94 KB
Format:
Adobe Portable Document Format